Aelis Farma (XPAR:AELIS) Debt-to-Asset : 0.15 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Aelis Farma Debt-to-Asset?

Aelis Farma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.09 Mil. Aelis Farma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2.95 Mil. Aelis Farma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €26.28 Mil. Aelis Farma's debt to asset for the quarter that ended in Dec. 2023 was 0.15.

Aelis Farma Debt-to-Asset Historical Data

The historical data trend for Aelis Farma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aelis Farma Debt-to-Asset Chart

Aelis Farma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.64

0.87

0.23

0.10

0.15

Aelis Farma Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial					0.23	0.06	0.10	0.13	0.15

Competitive Comparison of Aelis Farma's Debt-to-Asset

For the Biotechnology subindustry, Aelis Farma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aelis Farma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aelis Farma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Aelis Farma's Debt-to-Asset falls into.

Aelis Farma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Aelis Farma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.094	+	2.947)	/	26.281
	=	0.15

Aelis Farma's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.094	+	2.947)	/	26.281
	=	0.15

Aelis Farma (XPAR:AELIS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Aelis Farma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Aelis Farma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aelis Farma (XPAR:AELIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aelis Farma SA (XPAR:AELIS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

69O:Germany

Address

146, rue Leo Saignat, Bordeaux, FRA, 33077

Website

https://www.aelisfarma.com

Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases.

Aelis Farma (XPAR:AELIS) Headlines

No Headlines